
APPROVED PROFESSIONAL INFORMATION

SCHEDULING STATUS

S5

1. NAME OF THE MEDICINE

BUPROPION 150 mg XR Dyna extended release tablets

BUPROPION 300 mg XR Dyna extended release tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each BUPROPION 150 mg XR Dyna tablet contains 150 mg bupropion hydrochloride.

Each BUPROPION 300 mg XR Dyna tablet contains 300 mg bupropion hydrochloride.

BUPROPION XR Dyna is sugar free.

For the full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Film-coated extended release tablet.

BUPROPION 150 mg XR Dyna: Off-white to pale yellow, round, biconvex, coated tablets, imprinted with "L015" in black ink on one side and plain on other side.

BUPROPION 300 mg XR Dyna: Off-white to pale yellow, round, biconvex, coated tablets, imprinted with "L016" in black ink on one side and plain on other side.

APPROVED PROFESSIONAL INFORMATION

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

BUPROPION XR DYNA is indicated for the treatment of depression as defined by DSM IV Criteria. Following a satisfactory response, continuation with BUPROPION XR Dyna therapy is effective in preventing relapse and preventing recurrence of further depressive episodes.

4.2 Posology and method of administration

Therapy should be initiated by medical practitioners experienced in the treatment of depression.

Posology:

Initial treatment:

The initial dose of BUPROPION XR DYNA is 150 mg taken as a single daily dose in the morning. Patients who are not responding adequately to a dose of 150 mg/day may benefit from an increase to the usual adult target dose of 300 mg/day, given once daily. There should be an interval of at least 24 hours between successive doses.

Insomnia is a very common adverse event which is often transient. Insomnia may be reduced by avoiding dosing at bedtime (provided there is at least 24 hours between doses) or, if clinically indicated, dose reduction.

APPROVED PROFESSIONAL INFORMATION

Switching Patients from sustained release tablets:

When switching patients from sustained release tablets to extended release tablets; give the same total daily dose when possible. Patients who are currently being treated with sustained release tablets at 300 mg/day (e.g. 150 mg twice daily) may be switched to extended release tablets 300 mg once daily.

Special populations

Elderly: Greater sensitivity of some elderly individuals to BUPROPION XR DYNA cannot be ruled out, hence a reduced frequency and/or dose may be required (see section 4.4).

Renal Impairment: Treatment of patients with renal impairment should be initiated at a reduced frequency and/or dose, as BUPROPION XR DYNA and its metabolites may accumulate in such patients to a greater extent than usual (see section 4.4).

Liver Impairment: BUPROPION XR DYNA should be used with caution in patients with mild liver impairment. Because of increased variability in the pharmacokinetics in patients with mild hepatic cirrhosis, a reduced frequency of dosing should be considered (see sections 4.4 and 4.8), BUPROPION XR DYNA is contraindicated in patients with moderate to severe hepatic cirrhosis.

APPROVED PROFESSIONAL INFORMATION

Paediatric population

BUPROPION XR DYNA is not indicated for use in children or adolescents aged less than 18 years (see section 4.3).

Method of administration

BUPROPION XR DYNA tablets should be swallowed whole. The tablets should not be cut, crushed or chewed as this may lead to an increased risk of adverse effects including seizures.

4.3 Contraindications

- hypersensitivity to BUPROPION XR DYNA or to any of the excipients listed in 6.1
- patients under 18 years
- BUPROPION XR DYNA is contraindicated in patients with a seizure disorder
- BUPROPION XR DYNA should not be administered to patients currently being treated with any other preparation containing bupropion, as the incidence of seizures is dose dependent
- BUPROPION XR DYNA is contraindicated in patients undergoing abrupt discontinuation of alcohol or sedatives
- BUPROPION XR DYNA is contraindicated in patients with a current or previous diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was seen in this patient population when BUPROPION XR DYNA was administered

APPROVED PROFESSIONAL INFORMATION

- concomitant administration of BUPROPION XR DYNA with monoamine oxidase inhibitors (MAOIs) is contraindicated. At least 14 days should elapse between the discontinuation of MAOIs and initiation of treatment with BUPROPION XR DYNA
- liver disease, Child-Pugh grades B and C, range 7-13.

4.4 Special warnings and precautions for use

Seizures:

The recommended dose of BUPROPION XR DYNA should not be exceeded, since bupropion is associated with a dose-related risk of seizure.

BUPROPION XR DYNA should be discontinued promptly if patients experience hypersensitivity reactions during treatment (see section 4.8). Medical practitioners should be aware that symptoms may persist beyond the discontinuation of BUPROPION XR DYNA and clinical management should be provided accordingly.

The overall incidence of seizure with bupropion hydrochloride in clinical trials was approximately 0,1 %.

There is an increased risk of seizures occurring with the use of BUPROPION XR DYNA in the presence of predisposing risk factors, which lower the seizure threshold. Therefore, BUPROPION XR DYNA should not be administered to patients with one or more conditions predisposing to a lowered seizure threshold, which include:

- history of head trauma
- central nervous system (CNS) tumour

APPROVED PROFESSIONAL INFORMATION

- history of seizures
- concomitant administration of other medications known to lower the seizure threshold
excessive use of alcohol or sedatives (see section 4.3), diabetes treated with
hypoglycaemics or insulin and use of stimulants or anorectic medicines.

BUPROPION XR DYNA should be discontinued and not recommenced in patients who experience a seizure while on treatment.

Clinical worsening and suicide risk in adults associated with psychiatric disorders:

Patients with major depressive disorder, may experience worsening of their depression and or the emergence of suicidal ideation and behaviour, whether or not they are taking antidepressant medicines. This risk may persist until significant remission occurs. A casual role, however, for antidepressant medicine in inducing such behaviour has not been established. As improvement may occur during the first few weeks or more of treatment, patients being treated with BUPROPION XR DYNA should, nevertheless, be observed closely for clinical worsening (including development of new symptoms) and suicidality, especially at the beginning of a course of therapy or at any time of dose changes, either increases or decreases. Patients with a history of suicidal behaviour or thoughts, young adults and those patients exhibiting a significant degree of suicidal ideation prior to commencement of treatment are at a greater risk of suicidal thoughts or suicide attempts and should receive careful monitoring during treatment.

APPROVED PROFESSIONAL INFORMATION

The following symptoms have been reported in patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and non-psychiatric: anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness, impulsivity, akathisia, hypomania, and mania.

In addition, a meta-analysis of placebo controlled clinical trials of antidepressant medicines in adults with major depressive disorder and other psychiatric disorders showed an increased risk of suicidal thinking and behaviour associated with antidepressant use compared to placebo in patients less than 25 years old.

Patients (and caregivers of patients) should be alerted about the need to monitor for any worsening of their condition (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present. It should be recognised that the onset of neuropsychiatric symptoms could be related either to the underlying disease state or the medicine therapy and an appropriate patient assessment should be undertaken (see section 4.8).

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing BUPROPION XR DYNA, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour, especially if these symptoms are severe, abrupt in onset, or were not part

APPROVED PROFESSIONAL INFORMATION

of the patient's presenting symptoms. Although there is no need to taper BUPROPION XR DYNA upon discontinuation, the patient should be monitored for worsening of depressive symptoms following discontinuation.

Neuropsychiatric symptoms including mania and bipolar disorder:

Neuropsychiatric symptoms have been reported (see section 4.8.). In particular, psychotic and manic symptomatology has been observed, mainly in patients with a known history of psychiatric illness. Aggression, rage and violent behaviour may occur. Additionally, a major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone can increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Limited clinical data on use of BUPROPION XR DYNA in combination with mood stabilisers in patients with a history of bipolar disorder suggests a low rate of switch to mania.

Prior to initiating treatment with BUPROPION XR DYNA, patients should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.

Hepatic impairment:

BUPROPION XR DYNA is extensively metabolised in the liver to active metabolites, which are

APPROVED PROFESSIONAL INFORMATION

further metabolised. No statistically significant differences in the pharmacokinetics of bupropion were observed in patients with mild hepatic cirrhosis compared with healthy volunteers, but bupropion plasma levels showed a higher variability between individual patients.

Therefore, BUPROPION XR DYNA should be used with caution in patients with mild hepatic impairment and reduced frequency of dosing should be considered (see sections 4.3 and 5.2).

Renal impairment and elderly patients:

Bupropion is extensively metabolised in the liver to active metabolites which are further metabolised and excreted by the kidneys. Therefore, treatment of patients with renal impairment should be initiated at reduced frequency and/or dose as bupropion and its metabolites may accumulate in such patients to a greater extent than usual. The patient should be closely monitored for possible adverse effects (e.g. insomnia, dry mouth, seizures) that could indicate high bupropion or metabolite levels, toxic effects of elevated blood and tissue levels of bupropion and metabolites.

Clinical experience with BUPROPION XR DYNA has not identified any differences in tolerability between elderly and other adult patients, However, greater sensitivity of some elderly individuals cannot be ruled out, hence a reduced frequency and/or dose may be required (see section 5.2).

APPROVED PROFESSIONAL INFORMATION

Cardiovascular disease:

There is limited clinical experience of the use of BUPROPION XR DYNA to treat depression in patients with cardiovascular disease. A causal relationship between the use of BUPROPION XR DYNA and sudden death cannot be excluded. Care should be exercised if BUPROPION XR DYNA is used in these patients.

Children and Adolescents <18 years:

The safety and efficacy with the treatment of BUPROPION XR DYNA tablets in patients under 18 years of age have not been established. Treatment with antidepressants is associated with an increased risk of suicidal thinking and behaviour in children and adolescents with major depressive disorder and other psychiatric disorders (see section 4.3).

4.5 Interaction with other medicines and other forms of interaction

Medicines known to affect the CYP2B6 isoenzyme:

Bupropion is metabolised to its major active metabolite hydroxybupropion primarily by the cytochrome P450 IIB6 (CYP2B6) (see section 5.2).

Care should therefore be exercised when BUPROPION XR DYNA is co-administered with medicines known to affect the CYP2B6 isoenzyme (e.g. orphenadrine, cyclophosphamide, ifosfamide, ticlopidine, clopidogrel).

APPROVED PROFESSIONAL INFORMATION

Medicines metabolized by CYP2D6:

Although bupropion is not metabolised by the CYP2D6 isoenzyme, *in vitro* human P450 studies have shown that bupropion and hydroxybupropion are inhibitors of the CYP2D6 pathway.

In a human pharmacokinetic study, administration of bupropion increased plasma levels of desipramine. This effect was present for at least 7 days after the last dose of bupropion. Concomitant therapy with medicines predominantly metabolised by this isoenzyme (such as certain beta-blockers, anti-dysrhythmics, selective serotonin re-uptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), antipsychotics should be initiated at the lower end of the dose range of the concomitant medicine. If BUPROPION XR DYNA is added to the treatment regimen of a patient already receiving a medication metabolised by CYP2D6, the need to decrease the dose of the original medication should be considered, particularly for those concomitant medications with a narrow therapeutic index (see section 5.2.).

Citalopram:

Although citalopram is not primarily metabolised by CYP2D6, in one study, bupropion increased the C_{max} and AUC of citalopram by 30 % and 40 %, respectively.

Medicines known to induce metabolism:

Since bupropion is extensively metabolised, the co-administration of medicines known to induce metabolism (e.g. carbamazepine, phenobarbitone, phenytoin) or inhibit metabolism

APPROVED PROFESSIONAL INFORMATION

may affect its clinical activity.

Ritonavir:

In a series of studies in healthy volunteers, ritonavir (100 mg twice daily or 600 mg twice daily) or ritonavir 100 mg plus lopinavir 400 mg twice daily reduced the exposure of bupropion and its major metabolites in a dose dependent manner by approximately 20 to 80 %. This effect is thought to be due to the induction of bupropion metabolism. Patients receiving ritonavir may need increased doses of BUPROPION XR DYNA but the maximum recommended dose of BUPROPION XR DYNA should not be exceeded.

Alcohol:

There have been reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients drinking alcohol during bupropion hydrochloride treatment. The consumption of alcohol during BUPROPION XR DYNA treatment should be minimised or avoided.

Levodopa or amantadine:

Limited clinical data suggest a higher incidence of adverse events in patients receiving concurrent administration of bupropion and levodopa. Administration of BUPROPION XR DYNA to patients receiving either levodopa or amantadine concurrently should be undertaken with caution.

APPROVED PROFESSIONAL INFORMATION

Nicotine:

Concomitant use of BUPROPION XR DYNA and a Nicotine Transdermal System (NTS) may result in elevations of blood pressure.

Monoamine oxidase inhibitors (MAOIs):

Bupropion inhibits the reuptake of dopamine and norepinephrine. Concomitant use of monoamine oxidase inhibitors (MAOIs) and bupropion is contraindicated because there is an increased risk of hypertensive reactions if bupropion is used concomitantly with MAOIs. At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of treatment with BUPROPION XR DYNA. Conversely, at least 14 days should be allowed after stopping BUPROPION XR DYNA before starting an MAOI antidepressant.

Bupropion has been classified as possibly porphyrinogenic. It should be used only when no safe alternative is available, and precautions should be considered in vulnerable patients.

4.6 Fertility, pregnancy and lactation

Safety in pregnancy and lactation has not been established.

Pregnancy

Epidemiological studies of pregnancy outcomes following maternal exposure to bupropion in the first trimester have reported an association with increased risk of some congenital

APPROVED PROFESSIONAL INFORMATION

cardiovascular malformations, including ventricular septal defects and left ventricular outflow tract defects. These findings are not consistent across studies.

Breastfeeding

As bupropion and its metabolites are excreted in human breast milk, mothers should be advised not to breastfeed while taking BUPROPION XR DYNA.

Fertility

There is no data on fertility with BUPROPION XR DYNA.

4.7 Effects on ability to drive and use machines:

Patients should exercise caution before driving or use of machinery until they are reasonably certain **BUPROPION XR DYNA** tablets do not adversely affect their performance.

4.8 Undesirable effects

Tabulated list of adverse effects

System Organ Class	Frequency	Side effects
---------------------------	------------------	---------------------

APPROVED PROFESSIONAL INFORMATION

Blood and lymphatic system disorders	Frequency unknown	Ecchymosis, anaemia, leukocytosis, leukopenia, lymphadenopathy, pancytopenia, and thrombocytopenia, altered PT and/or INR, associated with haemorrhagic or thrombotic complications, when co-administered with warfarin
Immune system disorders	Frequent	Hypersensitivity reactions such as urticaria
	Less frequent	More severe hypersensitivity reactions including angioedema, dyspnoea/bronchospasm and anaphylactic shock, arthralgia, myalgia, fever, rash (symptoms resemble serum sickness)
Endocrine disorders	Frequency unknown	Hyperglycaemia, hypoglycaemia, syndrome of inappropriate antidiuretic hormone secretion
Metabolism and nutrition disorders	Frequent	Anorexia, weight loss
	Less frequent	Blood glucose disturbances
	Frequency unknown	Glycosuria

APPROVED PROFESSIONAL INFORMATION

Psychiatric disorders	Frequent	Insomnia, agitation, anxiety
	Less frequent	Confusion, depression, aggression, hostility, irritability, restlessness, hallucinations, abnormal dreams, depersonalisation, delusions, paranoid ideation
	Frequency unknown	Suicide attempt



APPROVED PROFESSIONAL INFORMATION

Nervous system disorders	Frequent	Headache, tremor, dizziness, taste disorders
	Less frequent	Concentration disturbances, seizures (see section 4.4), dystonia, ataxia, parkinsonism, incoordination, memory impairment, paraesthesia, syncope
	Frequency unknown	Emotional lability, derealization, euphoria, abnormal co-ordination, hyperkinesia, hypertonia, hyperesthesia, vertigo, amnesia, abnormal electroencephalogram (EEG), akinesia, aphasia, coma, dysarthria, dyskinesia, extrapyramidal syndrome, hypokinesia, increased libido, neuralgia, neuropathy, unmasking tardive dyskinesia
Eye disorders	Frequent	Visual disturbance
	Frequency unknown	Accommodation abnormality, dry eye, increased intraocular pressure angle-closure glaucoma, mydriasis
Ear and labyrinth disorders	Frequent	Tinnitus
	Frequency unknown	Deafness

APPROVED PROFESSIONAL INFORMATION

Cardiac disorders	Less frequent	Tachycardia, palpitations
	Frequency unknown	complete atrioventricular block, extrasystoles, myocardial infarction
Vascular disorders	Frequent	Increased blood pressure (sometimes severe), flushing
	Less frequent	Vasodilation, postural hypotension
	Frequency unknown	Hypertension, stroke, phlebitis, pulmonary embolism
Respiratory, thoracic and mediastinal disorders	Frequency unknown	Bronchospasm, pneumonia
Gastrointestinal disorders	Frequent	Dry mouth, gastrointestinal disturbance including nausea and vomiting, abdominal pain, constipation
	Frequency unknown	Gastric reflux, stomatitis, thirst, colitis, esophagitis, gastrointestinal haemorrhage, intestinal perforation, stomach ulcer
Hepato-biliary disorders	Less frequent	Elevated liver enzymes, jaundice, hepatitis
	Frequency unknown	Abnormal liver function, liver damage, pancreatitis



APPROVED PROFESSIONAL INFORMATION

Skin and subcutaneous tissue disorders	Frequent	Rash, pruritus, sweating
	Less frequent	Erythema multiforme and Stevens-Johnson syndrome
	Frequency unknown	Maculopapular rash, alopecia, angioedema, exfoliative dermatitis and hirsutism
Musculoskeletal, connective tissue and bone disorders	Less frequent	Twitching
	Frequency unknown	Leg cramps, fever/rhabdomyolysis, and muscle weakness
Renal and urinary disorders	Less frequent	Urinary frequency and/or retention
	Frequency unknown	Dysuria, urinary incontinence, cystitis
Reproductive system and breast disorders	Frequency unknown	Impotence, prostate disorder, abnormal ejaculation, dyspareunia, gynaecomastia, menopause, painful erection, salpingitis, vaginitis
General disorders and administrative site conditions	Frequent	Fever, asthenia, chest pain.
	Frequency unknown	Bruxism, gingivitis, glossitis, increased salivation, mouth ulcers, oedema of tongue, gum haemorrhage

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It

APPROVED PROFESSIONAL INFORMATION

allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions to SAHPRA via the online service for adverse drug reaction reporting by following the link:

<https://www.sahpra.org.za/Publications/Index/8>.

An email can be sent directly to the company, pharmacovigilance@pharmadynamics.co.za to ensure safety of the product.

4.9 Overdose

Signs and symptoms

Drowsiness, loss of consciousness and ECG changes such as conduction disturbances (including QRS prolongation) or dysrhythmias.

Acute ingestion of doses in excess of 10 times the maximum therapeutic dose has been reported.

Management of overdose

In the event of overdose, hospitalisation is advised.

ECG and vital signs should be monitored.

Ensure an adequate airway, oxygenation and ventilation. The use of activated charcoal is recommended. No specific antidote for bupropion is known.

Further management should be as clinically indicated or as recommended by the national

APPROVED PROFESSIONAL INFORMATION

poisons centre, where available.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other antidepressants

ATC code: N06 AX12

Pharmacological classification: A.1.2 Psycho-analeptics (antidepressants)

Bupropion is an inhibitor of the neuronal re-uptake of catecholamines (noradrenaline (norepinephrine) and dopamine) with minimal effect on the re-uptake of indolamines (serotonin) and does not inhibit monoamine oxidase. The mechanism of action of bupropion is unknown.

5.2 Pharmacokinetic properties

Absorption

Following oral administration of bupropion tablets to healthy volunteers, time to peak plasma concentrations for bupropion was approximately 5 hours. The absorption of bupropion is not significantly affected when taken with food. Bupropion and its metabolites exhibit linear kinetics following chronic administration of 150 to 300 mg per day.

Distribution

Bupropion is widely distributed with an apparent volume of distribution of approximately 2000

APPROVED PROFESSIONAL INFORMATION

L. Bupropion and hydroxybupropion are moderately bound to plasma proteins (84 % and 77 %, respectively).

The extent of protein binding of the threo-hydrobupropion metabolite is about half that seen with bupropion.

Biotransformation

Bupropion is extensively metabolised in humans. Three pharmacologically active metabolites have been identified in plasma: hydroxybupropion and the amino-alcohol isomers, threo-hydrobupropion and erythro-hydrobupropion. These have clinical importance, as their plasma concentrations are as high as or higher than those of bupropion.

Peak plasma concentrations of hydroxybupropion occur approximately 7 hours following administration of bupropion.

Erythro-hydrobupropion cannot be measured in the plasma after a single dose of bupropion. The active metabolites are further metabolised to inactive metabolites and excreted in the urine.

In vitro studies indicate that bupropion is metabolised to its major active metabolite hydroxybupropion primarily by CYP2B6, while cytochrome P450s are not involved in the formation of threo-hydrobupropion (see section 4.5).

Bupropion and hydroxybupropion are both relatively weak competitive inhibitors of the

APPROVED PROFESSIONAL INFORMATION

CYP2D6 isoenzyme with K_i values of 21 and 13,3 μM , respectively. In human volunteers known to be extensive metabolisers of the CYP2D6 isoenzyme, co-administration of bupropion and desipramine has resulted in 2- and 5-fold increases in the C_{max} and AUC, respectively, of desipramine. This effect was present for at least 7 days after the last dose of bupropion. Since bupropion is not metabolised by the CYP2D6 pathway, desipramine is not anticipated to affect the pharmacokinetics of bupropion. Caution is advised when bupropion is administered with substrates for the CYP2D6 pathway (see section 4.5).

In humans, there is no evidence of enzyme induction of bupropion or hydroxybupropion in volunteers or patients receiving recommended doses of bupropion for 10 to 45 days.

Elimination

Following oral administration of 200 mg of ^{14}C -bupropion in humans, 87 % and 10 % of the radioactive dose were recovered in the urine and faeces, respectively. The fraction of the dose of bupropion excreted unchanged was only 0,5 %, a finding consistent with the extensive metabolism of bupropion. Less than 10 % of this ^{14}C dose was accounted for in the urine as active metabolites.

The mean apparent clearance following oral administration of bupropion is approximately 200 L/hr and the mean elimination half-life of bupropion is approximately 20 hours.

The elimination half-life of hydroxy-bupropion is approximately 20 hours and its area under the plasma drug concentration versus time curve (AUC) at steady state is approximately 17 times

APPROVED PROFESSIONAL INFORMATION

that of bupropion. The elimination half-lives for threo-hydrobupropion and erythron-hydrobupropion are longer (37 and 33 hours, respectively) and steady-state AUC values are 8 and 1,6 times higher than that of bupropion, respectively. Steady-state for bupropion and its metabolites is reached within 8 days.

Pharmacokinetics in special patient groups

Elderly

Pharmacokinetic studies in the elderly have shown variable results. A single dose study showed that the pharmacokinetics of bupropion and its metabolites in the elderly do not differ from those in the younger adults. Another pharmacokinetic study, single and multiple doses, has suggested that accumulation of bupropion and its metabolites may occur to a greater extent in the elderly. Clinical experience has not identified differences in tolerability between elderly and younger patients, but greater sensitivity in older patients cannot be ruled out.

Patients with renal impairment

The elimination of bupropion and its major metabolites may be reduced by impaired renal function (see section 4.4).

Patients with hepatic impairment

The pharmacokinetics of bupropion and its active metabolites were not statistically significantly different in patients with mild cirrhosis (Child-Pugh grade A, range 5-6) when

APPROVED PROFESSIONAL INFORMATION

compared to healthy volunteers, although more variability was observed between individual patients. For patients with moderate to severe hepatic cirrhosis (Child Pugh grades B & C, range 7-13), a single dose of bupropion produced a C_{max} and AUC that were substantially increased (mean difference approximately 70 % and 3-fold, respectively) and more variable when compared to the values in healthy volunteers; the mean half-life was also longer (by approximately 40 %). For the metabolites, the mean C_{max} was lower (by approximately 30 to 70 %), the mean AUC tended to be higher (by approximately 30 to 50 %), the median T_{max} was later (by approximately 20 hrs), and the mean half-lives were longer (by approximately 2 to 4-fold) than in healthy volunteers (see section 4.3).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Cores

Glyceryl behenate

Hydrophobic colloidal silica

L-cysteine hydrochloride monohydrate

Polyvinyl alcohol

Coating

Colloidal silicon dioxide

Dibutyl sebacate

Ethyl cellulose

APPROVED PROFESSIONAL INFORMATION

Hydroxypropyl cellulose

Methacrylic acid copolymer dispersion

Povidone

Triethyl citrate

Imprinting ink – Opacode Black

Ammonium hydroxide

Iron oxide black

Isopropyl alcohol

N-butyl alcohol

Propylene glycol

Shellac glaze

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store at or below 25 °C.

APPROVED PROFESSIONAL INFORMATION

6.5 Nature and contents of container

150 mg:

30's: White opaque 100 mL HDPE bottle containing 30 tablets along with one molecular sieve 1 g sachet, one activated carbon 1 g sachet and one StabilOx® strip form sachet closed with white child resistant closure.

90's: White opaque 150 mL HDPE bottle containing 90 tablets along with one molecular sieve 1 g sachet, one activated carbon 1 g sachet and one StabilOx® strip form sachet closed with white child resistant closure.

500's: White opaque 500 mL HDPE bottle containing 500 tablets along with one molecular sieve 5 g sachet, one activated carbon 5 g sachet and one StabilOx® strip form sachet closed with white non child resistant closure.

300 mg:

30's: White opaque 100 mL HDPE bottle containing 30 tablets along with one molecular sieve 1 g sachet, one activated carbon 1 g sachet and one StabilOx® strip form sachet closed with white child resistant closure.

90's: White opaque 250 mL HDPE bottle containing 90 tablets along with one molecular sieve 1 g sachet, one activated carbon 1 g sachet and one StabilOx® strip form sachet closed with white child resistant closure.

500's: White opaque 500 mL HDPE bottle containing 500 tablets along with one molecular sieve 5 g sachet, one activated carbon 5 g sachet and one StabilOx® strip form sachet

APPROVED PROFESSIONAL INFORMATION

closed with white non child resistant closure.

**6.6 Special precautions for disposal of a used medicine or waste materials derived
from such medicine and other handling of the product**

No special requirements.

7. HOLDER OF THE CERTIFICATE OF REGISTRATION:

Pharma Dynamics (Pty) Ltd

1st Floor, Grapevine House, Steenberg Office Park

Silverwood Close

Westlake, Cape Town

7945, South Africa

8. REGISTRATION NUMBER(S)

BUPROPION 150 mg XR Dyna: 54/1.2/0183.181

BUPROPION 300 mg XR Dyna: 54/1.2/0184.182

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorization: 27 June 2023

10. DATE OF REVISION OF THE TEXT